Insider Stock Trading History of Lamattina John L


The following table details the trading activities (stock purchases, stock sales, and stock option exercises) reported to the Securities and Exchange Commission (SEC) by insider Lamattina John L since year 2005. The trader's CIK number is 1216074. At the time of this reporting, Lamattina John L is the Director of Ligand Pharmaceuticals Inc . (stock ticker symbol LGND). See this page for all insider trading activities at Ligand Pharmaceuticals Inc .

Note that in the past LAMATTINA JOHN L also reported insider trading activities as an insider of the following companies:
Stock purchases, sales, and option exercises reported by insider Lamattina John L since 2005.
  Trade Date   Symbol Company Name (Issuer) Trade Type     Shares       Price ($)   Value ($)
2018-09-04 LGND Ligand Pharmaceuticals Inc Option Ex 3,335 12.53 41,787
2018-09-04 LGND Ligand Pharmaceuticals Inc Sale 3,335 254.96 850,291
2018-06-04 LGND Ligand Pharmaceuticals Inc Option Ex 4,000 12.53 50,120
2018-06-04 LGND Ligand Pharmaceuticals Inc Sale 4,000 194.51 778,040
2018-03-05 LGND Ligand Pharmaceuticals Inc Option Ex 3,335 10.12 33,750
2018-03-05 LGND Ligand Pharmaceuticals Inc Sale 3,335 160.90 536,604
2017-11-17 LGND Ligand Pharmaceuticals Inc Option Ex 4,000 10.12 40,480
2017-11-17 LGND Ligand Pharmaceuticals Inc Sale 4,000 139.79 559,160
2014-03-18 LGND Ligand Pharmaceuticals Inc Option Ex 5,000 8.97 44,850
2014-03-18 LGND Ligand Pharmaceuticals Inc Sale 5,000 78.83 394,150
2011-08-10 HGSI Human Genome Sciences Inc Option Ex 12,009 2.09 25,098
2011-03-11 LGND Ligand Pharmaceuticals Inc Buy 10,000 9.82 98,190
2009-03-13 HGSI Human Genome Sciences Inc Buy 10,000 .72 7,190
2008-11-12 HGSI Human Genome Sciences Inc Buy 20,000 2.19 43,700
2007-06-15 PFE Pfizer Inc Sale 36,066 26.48 955,027
2007-02-07 PFE Pfizer Inc Option Ex 13,800 18.35 253,230
2007-02-07 PFE Pfizer Inc Sale 13,800 26.54 366,252
2005-05-06 PFE Pfizer Inc Sale 39,789 27.82 1,106,731

Insider trading activities including stock purchases, stock sales, and option exercises listed in the above table cannot be completely guaranteed as to their accuracy. For more information regarding the trades made by Lamattina John L (Director of Ligand Pharmaceuticals Inc at the time of this reporting) see the Securities and Exchange Commission (SEC) website.